Market Herald logo

Subscribe

Be the first with the news that moves the market
  • NeuroScientific Biopharmaceuticals (NSB) has completed its dosing stage of the Intraocular Pressure Glaucoma model (IOP model) on pigs
  • It says it’s too early to judge the success of the study, with analysis of a large number of histological samples and neuronal markers yet to take place
  • The company is looking forward to receiving results from the experiment
  • If successful, this will be a major outcome in ophthalmology
  • NeuroScientific is up 1.82 per cent on the market today and is trading at 28¢ apiece

NeuroScientific Biopharmaceuticals (NSB) has completed its dosing stage of the Intraocular Pressure Glaucoma model (IOP model) on pigs.

Ten animals have successfully gone through the treatment procedure, although it is still too early to judge the success of the study, which requires analysis of a large number of histological samples and neuronal markers that’s yet to be complete.

However, the company is pleased to report that execution of the experimental stage by the research team at the Lions Eye Institute was at the highest level and exceeded its expectations.

“We are eagerly waiting for the data from this pivotal pre-clinical study in our ophthalmology program and expecting to report the results by the end of this
month,” the company told the market.

Success in this study would be a major outcome in ophthalmology and would represent a major commercial opportunity at the Glaucoma field.

Positive results will allow NeuroScientific to progress in testing EmtinB in human Glaucoma patients next year. The company says this will provide the first evidence of the potential efficacy of EmtinB in patients.

Glaucoma is the leading cause of irreversible blindness in the world and affects over 300,000 Australians. Currently, there is no cure for the disease.

NeuroScientific also reported that the final data from its CVM mouse model is expected this week. It says technical issues with the fluorescence scanning equipment had caused a slight delay in finalising the study.

“Other than that, the experimental work was conducted as per the original protocol with no safety and toxicology events,” the company added.

NeuroScientific is up 1.82 per cent on the market today and is trading at 28¢ apiece at 1:24 pm AEDT.

NSB by the numbers
More From The Market Herald
The Market Herald Video

" Next Science’s (ASX:NXS) CEO submits resignation

Next Science’s (ASX:NXS) CEO has announced her intention to retire before June 30, 2023.
The Market Herald Video

" Race Oncology (ASX:RAC) completes first-phase Zantrene leukaemia trial

Cancer treatment company Race Oncology (ASX:RAC) has completed the latest stage of its first-phase trial for…
The Market Herald Video

" Immutep (ASX:IMM) publishes “favourable” interim data from second-phase efti trial

Immutep (ASX:IMM) has published new interim data from Part A of its second-phase TACTI-002 trial showing…

" Microba Life Sciences (ASX:MAP) partners with Midnight Health

Microba Life Sciences (ASX:MAP) has signed a strategic partnership agreement with healthcare company, Midnight Health, to…